Latest Safety News

Zimplats Holdings reported a strong FY2026 with revenue climbing 57% to US$1.3 billion and profit before tax soaring 484% to US$387.5 million, driven by higher metal prices, increased ore volumes, and improved operational efficiency.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Elevra Lithium posted a $44 million profit in FY26 after merging Sayona Mining and Piedmont Lithium, overcoming temporary mining challenges and securing full funding for the North American Lithium expansion.

Civmec delivered a robust FY26 with 11.4% revenue growth and a 22.5% jump in net profit, underpinned by a diversified project pipeline and strategic defence expansion.

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Saferoads Holdings (ASX:SRH) doubled its revenue to $12.47 million in FY2026, swinging to a $711,000 profit from continuing operations after divesting its Road Safety Rental business. The company declared a fully franked final dividend of 0.5 cents per share.

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Redox Limited posted a strong FY26 with record revenue of $1.33 billion, a 19.2% jump in statutory net profit, and a 4% dividend increase, while announcing a board leadership transition.

Horizon Oil Limited delivered record FY26 production of 2.15 million barrels of oil equivalent and expanded its reserves by 51% to 13.6 million boe, driven by strategic acquisitions and disciplined capital management.